Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.38 |
| ▸ | PDXK | O00764 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 2/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4713441 | 0.79 | AURKA (0.51) | AURKAHTTFLT3LRRK2 | |
| SCHEMBL14809680 | 0.78 | PGK1 (0.39) | PDXKPGK1AGTR1AGTR2HTT | |
| SCHEMBL4405613 | 0.76 | MERTK (0.49) | FLT3MERTK | |
| SCHEMBL1521623 | 0.75 | HTT (0.55) | PGK1AGTR1AGTR2HTTALDH1A1 | |
| SCHEMBL12409766 | 0.72 | LRRK2 (0.55) | CYP1A2LRRK2 | |
| SCHEMBL14410940 | 0.72 | PDXK (0.32) | PDXKAGTR1AGTR2HTT | |
| SCHEMBL15624865 | 0.68 | AGTR1 (0.41) | PDXKAGTR1AGTR2ALDH1A1HPGD | |
| SCHEMBL14810588 | 0.67 | YTHDC1 (0.40) | PDXKALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL11916193 | 0.67 | CYP1A2 (0.42) | AURKAPGK1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL18181689 | 0.66 | AURKA (0.46) | AURKAFLT3LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188113-B2 | For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | AURKA 303/4885PDXK 130/4885PGK1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.